Compare Becton Dickinson and Co (BDX) vs iShares MSCI Singapore ETF (EWS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs iShares MSCI Singapore ETF — how do they compare? Becton Dickinson and Co trades at $181.27 (market cap $49.41B), while iShares MSCI Singapore ETF trades at $33.64. The key difference: Becton Dickinson and Co pays a 2.32% dividend while iShares MSCI Singapore ETF pays none. Which is the better fit depends on your goals.
| BDX | EWS | |
|---|---|---|
Market Cap | $49.41B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $185.39 | $33.92 |
52-Week Low | $138.62 | $26.71 |
Enterprise Value | $65.51B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $180.64, up 0.56% today, near its consensus price target of $183. The stock shows bullish technical signals with strong moving averages and recent earnings beats in Q2 2026. Revenue growth is steady, with Q3 2026 reaching $5 billion, though margins face pressure from tariffs. The company maintains a Dividend Aristocrat status with consistent payouts.
Outlook is cautiously optimistic with analyst consensus leaning buy, but risks include margin compression and debt levels. The stock offers stability through dividends and sector resilience, yet investors should monitor earnings sustainability and competitive threats in the medical technology space.
EWS, the iShares MSCI Singapore ETF, trades at $33.68, up 1.54% today and near its 52-week high. Technical indicators show a bullish trend with strong moving average support, though oscillators signal overbought conditions. The ETF benefits from Singapore's economic resilience, AI-driven growth prospects, and a 3.97% dividend yield, with institutional interest rising as Amundi increased holdings by 4.8% in Q2 2026 (SEC filing, 2026-08-05).
Outlook is positive due to Singapore's market reforms and AI infrastructure investments, but risks include concentrated financial sector exposure and regional economic volatility. The bullish technical setup and institutional accumulation support upside potential, though overbought RSI levels warrant caution for near-term entries.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →
